Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 51

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
 SCHEDULE OF REPORTABLE SEGMENT LOSS 

    $1  
    $2  
    $3  
    $4 

    Three
    months ended  
    Six
    months ended 

    June
    30  
    June
    30 

    2025  
    2024  
    2025  
    2024 
  
    Research
    and development: 

    External
    research and development 
    $1,687,877  
    $923,864  
    $4,003,989  
    $1,704,764 
  
    Internal
    personnel costs 
     479,237  
     790,109  
     973,965  
     1,600,351 
  
    Total research
    and development 
     2,167,114  
     1,713,973  
     4,977,954  
     3,305,115 
  
    General and
    administrative 
     2,289,649  
     2,394,912  
     4,051,368  
     4,747,009 
  
    Other income,
    net 
     (15,547) 
     (93,618) 
     (55,676) 
     (230,180)
  
    Change
    in fair value of convertible promissory notes 
     787,703  
     -  
     787,703  
     - 
  
    Net
    loss 
    $5,228,919  
    $4,015,267  
    $9,761,349  
    $7,821,944 

NOTE
10: SUBSEQUENT EVENTS

The
Company evaluated subsequent events from June 30, 2025, the date of these unaudited condensed consolidated financial statements, through
August 13, 2025, which represents the date the condensed consolidated financial statements were issued, for events requiring recognition
or disclosure in the condensed consolidated financial statements for the six months ended June 30, 2025. The Company concluded that no
events have occurred that would require recognition or disclosure in the condensed consolidated financial statements except for the conversion
of the Notes on July 27, 2025 and the related issuance of the July 2025